Q4 FY25 Results Presentation
Released
Released
Announcement PDF
FOCUSING ON NATURAL
PRODUCTS THAT PROMOTE
CALMNESS, SUPPORT MIND &
MUSCLE RELAXATION &
IMPROVE SLEEP
Q4FY25 RESULTS PRESENTATION
Date: 31 July 2025
ABOUT THE CALMER CO.
The Calmer Co. International Limited (ASX:CCO) is a fast-growing beverage company
leveraging a global opportunity in kava and other natural products that replace alcohol and
support relaxation and sleep.
Our products are delivered to consumers globally through e-commerce channels and bluechip retail distribution partners, supported by a traceable and transparent farm to shelf
supply chain.
The product range includes drinking powders,
natural and flavoured kava shots, concentrates
and capsules, sold under the brands Fiji Kava,
Taki Mai and Danodan Hempworks in
markets including USA, Australia,
New Zealand, China and
the Pacific Islands.
The global kava root
extract market size
reached USD 1.6 Billion in
2024. Looking forward,
IMARC Group expects the
market to reach USD 5.6
Billion by 2033, exhibiting
a growth rate (CAGR) of
14.11% during 2025-2033.
Source: https://www.imarcgroup.com/kava-root-extract-market
FOUNDATIONS FOR SCALE & SUCCESS
•
•
•
•
Quality Certification Schemes e.g. GMP, Organic, Fair Trade
Public-Private Partnerships
Industry-led Associations & Codes of Practice
Export Market Activation e.g. Amazon & DTC, Major Brand
Wholesale, Retail
•
Government Support e.g. Ministries of Agriculture, Health,
Trade
Regional Bodies e.g. Pacific Islands Forum, MSG
Diplomatic Channels e.g. trade missions, bilateral trade
agreements
Cultural & Traditional Authority Endorsement
Border Enforcement Mechanisms
Traceability & Testing Protocols
•
•
•
•
•
•
•
•
•
•
National Standards e.g. Fiji, Tonga, Vanuatu Codex-aligned
standards
Global Benchmarks Alignment e.g. CODEX, ISO, FSANZ for
import
Scientific & Geographic Indication Laws
Controlled Substance Classification
Export/Import Compliance Laws
FOUNDATIONS FOR SCALE & SUCCESS
STRATEGIC PILLARS
THE WORLD'S LEADING NATURAL RELAXATION COMPANY
Regional Sourcing
& Innovation
-
-
PACIFIC ISLAND
REGIONAL
SOURCING
FIJI EXCELLENCE
IN QA & SERVICE
CO2
EXTRACTION
ESG STORY
Direct to Consumer
Inc. Amazon
-
-
AMAZON
USA & AU
SALESFORCE
WEBSITES (FK,
TM and DN)
HIGH-MARGIN,
HIGHAWARENESS DTC
FOCUS
Profitable &
Scalable Retail
Wholesale (Bulk)
Ingredients
-
MAJOR RETAIL
-
-
SUPPORTING
PHARMACY &
NUTRITION
BEVERAGE & KAVA
SNACK BRANDS
-
COMPLEMENTARY
MEDICINES
-
CO-MANUFACTURE
& FLAVOUR HOUSES
-
KAVA HOSPITALITY
-
-
HIGH-EXPOSURE,
TRIAL & RESALE
TO MAINSTREAM
AU & GLOBAL
REGIONAL SOURCING & INNOVATION
Serves as a roadmap to establishing a globally
competitive and sustainable kava supply
chain that supports quality standards,
innovation, regulatory improvements, and
market expansion.
The Calmer Co is well positioned to support a
regional supply chain given increased global
demand for kava which will further de-risk
against adverse weather events and any
anticipated pricing volatility.
Solomon Islands kava export pathway to Fiji
now open and strategic partners appointed in
Solomon Islands and PNG to support regional
supply.
COMMERCIAL FOCUS
KAVA IN GROWTH
CAPITALISE ON PILLAR 1
• Growing US demand creating new customers and
consumers while ANZ markets in steady growth
• Grow our core brands through effective and efficient
channels, utilising our innovation and agility advantage
• Channels are evolving quickly from online to retail,
hospitality and subsequent wholesale
opportunities
• Take advantage of the growing complementary
medicine market and rapidly emerging beverage
brands
Regional Sourcing
& Innovation
Direct to Consumer
Inc. Amazon
Profitable &
Scalable Retail
Wholesale (Bulk)
Ingredients
Q4 FY25
▪ Platform for future profitable growth with
improved GP and OP
▪ US now 41% of Sales Mix > #1 by Q1FY26
▪ Amazon forecasting 45% growth in kava /
broader market expanding at over 16% CAGR
▪ +500 kava bars across the USA, reflecting the
broad rise in demand and acceptance
▪ Strong inventory position in US
▪ Spreading product and channel mix
▪ Q4: Online 52%
Retail 35%
Wholesale 13%
▪ Q4: Powder 79% Extract 13% Other 8%
COMMERCIAL PERFORMANCE
FY25
$1.9m
unaudited
Revenue
6%
Vs Q3FY25
WHOLESALE
Q4 FY25
Revenue
Q4 FY25
Revenue
$607k
$8m
Revenues
AMAZON
86%
Vs FY24
$242k
28%
Vs Q3FY25
56%
Vs Q3FY25
Key Operating Insight
Revenues Up 6% in Q4 vs Q3
US Market Growth
Wholesale Continues to Grow
All channels in growth (wholesale, retail &
Amazon/D2C).
Amazon driving significant growth in USA, now
supported by expanding wholesale opportunity
FY25 unaudited revenue breaks $8M, an 86%
growth of FY24
Broader market opportunity, including NPD
‘Flavoured Kava Shots’ and ‘Kava Tinctures’
Amazon Markets, yet to impact revenue
Wholesale sales climb 56% vs Q3, leading to a
broader balance across the revenue mix, now
accounting for 13% of the sales mix.
Powders remain #1 with 79% of sales value.
AMAZON & D2C
Online remains the key platforms for consumer engagement, education and
conversions, with limited barriers to new products
Q4FY25 Amazon & D2C
• Amazon Revenue up 28% to $607k
• Improved marketing & portfolio
• Identify valuable sub-categories & launch NPD (shots, tinctures, powder variants)
• Building brand diversity (TakiMai now +30% vs <7% Jan 25)
• Increased share of category sales (3% to 7%)
• Subscription sales now 28% of monthly sales volume
• D2C: Onboarding Acuity for Advertising, Social & D2C Management,
including new FijiKava.com and TakiMai.com build for Q1
Launch
STRATEGIC RETAIL
Key platform in raising kava-product category and brand awareness, increase
trial, and establish on going usage in the mainstream.
Q4FY25 Retail
• RRP increase implemented in both majors including wholesale price increase with
Coles [4th and 11th June]
• Successful ranging with Woolworths (50g), launched late June in 989 stores
• Further expanded 150g distribution in Coles (+27.1%)
• Revenue +2.4% with improved margins and revenue from ranging and price
changes to see effect in Q1FY26
WHOLESALE
Leveraging vertical integration advantage in a market with growing customers
and limited suppliers or expertise
Q4FY25 Wholesale
• Revenue up by 56% contributing now 13% of sales volume
• First production & sale of high potency kava extract
• Identified & formulated three core high potency extract formats for wholesale
channel
• B2B Sales Platform built for US (Bars & Retail Stores)
• Pipeline of potential customers building awaiting samples of new products
• IMCD North America Complementary Medicine Focus
CEO SUMMARY
"Q4 was another strong step toward breakeven, with revenue up 6%
to $1.9M. Amazon USA and wholesale channels delivered standout
growth, while retail remained solid with Woolworths orders
commencing.
We’ve completed our digital transition to the Acuity platform, setting
the stage for scalable eCommerce growth. Margin gains from new
retail pricing and our first CO₂ extract sale further validate our
strategy.
With strengthened foundations and high-margin channels
accelerating, we are well positioned for sustainable, profitable growth
in FY26.
Zane Yoshida
Founder & CEO
The Calmer Co
For the full year, we reached $8 million in unaudited revenue, an 86%
increase on FY24, and nearly 5x growth in just two years. With highermargin formats, scalable infrastructure, and strong momentum
heading into Q1, our focus remains on delivering profitable growth
and pushing toward breakeven."
View full release and join the conversation on our Investor Hub
Q4 Results Webinar
Thank you.
We invite all investors to join our quarterly results
webinar.
Register for the Q4 FY2025 Investor Webinar
Investor Hub
To view this and other ASX releases please go to our
Investor Hub.
Join the conversation on Investor Hub
Share your feedback
Discover